MOESM1 of Knowledge of bloodless medicine among nurses at the Medical/Surgical Directorate of Komfo Anokye Teaching Hospital, Ghana; a descriptive cross sectional study

Additional file 1: Table S1. Knowledge of bloodless surgery risk factors of BM and reasons for demand of BM. Only 29.7% of the participants knew the risk factors of BM. The commonly known risk factors were organ injury/death (50.0%). 97.5% of the participants knew that more doctors other than nurse (3.3%) and patients (0.8%) request for blood transfusion. The most common reason for alternative medicine was religious beliefs (53.7%), followed by fear of transfusion complications (24.8%), ethical issues (9.9%), personal issue (9.0%) and economic issues (3.3%) respectively. Majority (71.9%) of the participants had never heard of BS. Most of the participants who were aware heard it from an internet search (97.8%), whiles others read it from the medical journal (14.4%), medical textbooks (52.2%), media (42.2%) and seminar (16.7%)

Additional file 1: of Knowledge of complications of diabetes mellitus among patients visiting the diabetes clinic at Sampa Government Hospital, Ghana: a descriptive study

Data set on which conclusion of this manuscript was based upon. (XLSX 54 kb

Association between adverse pregnancy outcome and maternal age.

<p>Association between adverse pregnancy outcome and maternal age.</p

Spearman rho partial correlation between maternal age and OS biomarkers and AGMs.

<p>Spearman rho partial correlation between maternal age and OS biomarkers and AGMs.</p

Serum levels of AGMs and OS biomarkers in relation to maternal age.

<p>Serum levels of AGMs and OS biomarkers in relation to maternal age.</p

A Rapid, Shallow Whole Genome Sequencing Workflow Applicable to Limiting Amounts of Cell-Free DNA.

BackgroundSomatic copy number alterations (sCNAs) acquired during the evolution of breast cancer provide valuable prognostic and therapeutic information. Here we present a workflow for screening sCNAs using picogram amounts of cell-free DNA (cfDNA) and single circulating tumor cells (CTCs).MethodsWe repurposed the Ion ReproSeq PGS™ preimplantation genetic testing kit to perform shallow whole genome sequencing on 178 cfDNA samples (300 pg) and individual CTCs from 10 MBC patients with metastatic breast cancer (MBC) recovered by CellSearch®/DEPArray™. Results were analyzed using a tailored ichorCNA workflow.ResultssCNAs were detected in cfDNA of 41/105 (39%) patients with MBC and 3/23 (13%) primary breast cancers on follow-up (PBC FU), all of whom subsequently relapsed. In 8 of 10 MBCs, individual CTCs had a higher copy number count than matched cfDNA. The median tumor fraction detected by ichorCNA was 0.34 (range 0.17-0.58) for MBC and 0.36 (range 0.31-0.37) for PBC FU. Patients with detectable tumor fraction (≥ 0.1) and TFx and OncomineTM variants had significantly lower overall survival rates (P values P = 0.002 and P ConclusionsThe ReproSeq PGS assay is rapid, at approximately $120 per sample, providing both a sCNA profile and estimation of the tumor DNA fraction from limiting cfDNA template (300pg) and individual CTCs. The approach could be used to examine the copy number landscape over time to guide treatment decisions, support future trial designs, and be applied to low volume blood spot samples enabling remote monitoring